Re: Farmas USA
NAVB
Comunica que en el suplemento de Nature de octubre aparecerán nuevos datos de estudios en colaboración sobre su plataforma Manocept y la creación de un panel de expertos relativo a Manocept.
“The collaborative studies presented in this Nature publication focused on establishing the ability of a fluorescent-labeled tilmanocept to target macrophages in three disease states which are representative of broader macrophage-associated disorders: Rheumatoid Arthritis (RA), Kaposi’s Sarcoma (KS) and Tuberculosis (TB),” said Frederick Cope, PhD, FACN, Senior Vice President and Chief Science Officer at Navidea. “The data indicate that CD206-targeting using Manocept-derived molecules may prove to be a potent tool for addressing unmet clinical needs such as localizing, staging and assessing disease activity in multiple therapeutic areas.”
"In connection with publication of this positive initial data, Navidea also announces the formation of its Manocept Advisory Board"
http://finance.yahoo.com/news/navidea-biopharmaceuticals-manocept-platform-featured-165900556.html
«Después de nada, o después de todo/ supe que todo no era más que nada.»
